利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.04 秒)

    TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS
    11.
    发明申请
    TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS 有权
    抗生素代谢物的超耐热组合物

    公开(公告)号：US20100216880A1

    公开(公告)日：2010-08-26

    申请号：US12614216

    申请日：2009-11-06

    申请人： Dario Norberto R. Carrara ,  Arnaud Grenier

    发明人： Dario Norberto R. Carrara ,  Arnaud Grenier

    IPC分类号： A61K31/216 ,  A61P21/00

    CPC分类号： A61K9/06 ,  A61K9/0014 ,  A61K31/216 ,  A61K31/56 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38

    摘要： The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.

    摘要翻译： 本发明一般涉及经皮或经粘膜给药抗胆碱能药如奥昔布宁的组合物或制剂。 本发明利用新型的递送载体，并且是基本上不含有无臭和无刺激性的透皮制剂，其基本上不含长链脂肪醇，长链脂肪酸和长链脂肪酸酯。 公开了一种用于用这些制剂治疗患有尿失禁的受试者的方法，同时减少药物的峰值浓度和与口服抗胆碱能药物相关的不期望的副作用的发生率。

    TRANSDERMAL DELIVERY OF SYSTEMICALLY ACTIVE CENTRAL NERVOUS SYSTEM DRUGS
    12.
    发明申请
    TRANSDERMAL DELIVERY OF SYSTEMICALLY ACTIVE CENTRAL NERVOUS SYSTEM DRUGS 审中-公开
    系统主动中枢神经系统药物的转运

    公开(公告)号：US20070225379A1

    公开(公告)日：2007-09-27

    申请号：US11755923

    申请日：2007-05-31

    申请人： Dario Norberto Carrara ,  Arnaud Grenier ,  Igno Alberti ,  Laetitia Henry ,  Celine Decaudin

    发明人： Dario Norberto Carrara ,  Arnaud Grenier ,  Igno Alberti ,  Laetitia Henry ,  Celine Decaudin

    IPC分类号： A61K47/00 ,  A61K31/025

    CPC分类号： A61K47/10 ,  A61K9/006 ,  A61K9/08 ,  A61K9/7015 ,  A61K31/025 ,  A61K31/135 ,  A61K31/27 ,  A61K31/404 ,  A61K31/427 ,  A61K31/428 ,  A61K31/439 ,  A61K31/4468 ,  A61K31/4745 ,  A61K47/08

    摘要： The invention relates to a transdermal or transmucosal non-occlusive, semi-solid pharmaceutical formulation that includes at least one systemically active agent that acts on the Central Nervous System (CNS) of a mammal; and a permeation enhancing solvent system present in an amount sufficient to solubilize the at least one active ingredient. The permeation enhancing solvent system includes a pharmaceutically acceptable monoalkyl ether of diethylene glycol; a pharmaceutically acceptable glycol; preferably also a fatty alcohol and or a fatty acid; and a mixture of a C2 to C4 alcohol and water so that the permeation enhancing solvent system (a) inhibits crystallization of the at least one active ingredient on a skin or mucosal surface of a mammal, (b) reduces or prevents transfer of the formulation to clothing or to another being, (c) modulates biodistribution of the at least one active agent within different layers of skin, (d) facilitates absorption of the at least one active agent by a skin or a mucosal surface of a mammal, or (e) provides a combination of one or more of (a) through (d).

    摘要翻译： 本发明涉及透皮或透粘膜非闭塞性半固体药物制剂，其包括作用于哺乳动物的中枢神经系统（CNS）的至少一种全身活性剂; 和渗透增强溶剂系统，其量足以溶解至少一种活性成分。 渗透增强溶剂系统包括药学上可接受的二甘醇单烷基醚; 药学上可接受的二醇; 优选还包括脂肪醇和/或脂肪酸; 和C 2〜C 4醇与水的混合物，使得渗透促进溶剂体系（a）抑制至少一种活性成分在皮肤上的结晶或 哺乳动物的粘膜表面，（b）减少或阻止制剂向衣服或另一种转移，（c）调节至少一种活性剂在不同皮肤层内的生物分布，（d）促进吸收至少 一种由哺乳动物的皮肤或粘膜表面活性剂，或（e）提供（a）至（d）中的一种或多种的组合。

    Transdermal pharmaceutical formulation for minimizing skin residues
    14.
    发明申请
    Transdermal pharmaceutical formulation for minimizing skin residues 有权
    用于最小化皮肤残留物的透皮药物制剂

    公开(公告)号：US20060153905A1

    公开(公告)日：2006-07-13

    申请号：US11371042

    申请日：2006-03-07

    申请人： R. Carrara ,  Arnaud Grenier ,  Celine Besse

    发明人： R. Carrara ,  Arnaud Grenier ,  Celine Besse

    IPC分类号： A61K9/70

    CPC分类号： A61K9/7007 ,  A61K9/0014 ,  A61K9/006 ,  A61K9/06 ,  A61K31/025 ,  A61K31/435 ,  A61K47/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/32 ,  A61K47/38 ,  Y10S514/946 ,  Y10S514/947

    摘要： This invention relates to novel transdermal or transmucosal pharmaceutical formulation which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The novel formulation includes at least one pharmacologically active ingredient, and a solvent system having a monoalkylether of diethylene glycol and a glycol present in specified ratios, and a mixture of water and alcohol. The invention also relates to a method for inhibiting or delaying crystallization of an active agent in a pharmaceutical formulation.

    摘要翻译： 本发明涉及新型透皮或透粘膜药物制剂，其减少其他个体的污染的发生以及使用者的衣服的转移。 该新型制剂包括至少一种药理学活性成分，和具有二乙二醇的单烷基醚和特定比例的二醇的溶剂体系，以及水和醇的混合物。 本发明还涉及抑制或延迟药物制剂中活性剂结晶的方法。

    NESTORONE®/ESTRADIOL TRANSDERMAL GEL
    15.
    发明申请
    NESTORONE®/ESTRADIOL TRANSDERMAL GEL 有权
    NESTORONE®/ ESTRADIOL TRANSDERMAL GEL

    公开(公告)号：US20130045953A1

    公开(公告)日：2013-02-21

    申请号：US13515552

    申请日：2010-12-17

    申请人： Regine Sitruk-Ware ,  Dario Norberto Ramon Carrara ,  Arnaud Grenier

    发明人： Regine Sitruk-Ware ,  Dario Norberto Ramon Carrara ,  Arnaud Grenier

    IPC分类号： A61K31/57 ,  A61P15/18

    CPC分类号： A61K31/565 ,  A61K9/0014 ,  A61K31/57 ,  A61K2300/00

    摘要： The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.

    摘要翻译： 本发明公开了用于确保两性生育年龄的妇女的组合物和方法，其确保具有额外的健康益处的避孕措施以及绝经后妇女，其中提供具有额外医疗益处的激素疗法，例如血栓形成风险降低的潜力。 上述组合物包含NES作为无雄激素和雌激素而不是糖皮质激素作用的有效的孕激素和抗iov药，并与配制用于非口服透皮给药的雌二醇组合作为特定的日剂量。

    LOW-FRIABILITY, PATIENT-FRIENDLY ORALLY DISINTEGRATING FORMULATIONS
    18.
    发明申请
    LOW-FRIABILITY, PATIENT-FRIENDLY ORALLY DISINTEGRATING FORMULATIONS 审中-公开
    低适应性，患者友好的ORALLY DISINC制剂

    公开(公告)号：US20070196494A1

    公开(公告)日：2007-08-23

    申请号：US11670293

    申请日：2007-02-01

    申请人： Arnaud Grenier ,  Celine Decaudin ,  Dario Norberto Carrara ,  Ubaldo Conte ,  Lauretta Maggi

    发明人： Arnaud Grenier ,  Celine Decaudin ,  Dario Norberto Carrara ,  Ubaldo Conte ,  Lauretta Maggi

    IPC分类号： A61K31/78

    CPC分类号： A61K9/0056 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2095 ,  A61K31/78

    摘要： The present invention relates to a rapidly disintegrating orally administratable solid dosage formulation that includes at least one active ingredient, at least one first disintegration agent that is at least one type-C methacrylic acid copolymer according to the U.S. Pharmacopoeia National Formulary US/NF, a second disintegration agent of crospovidone or a cross-linked povidone polymer derivative thereof, and a non-cariogenic diluent that does not increase glucose blood levels. The at least one first disintegration agent does not function as an enteric coating, insulation coating intended to protect active ingredient(s), or coating intended to mask taste or smell. The solid dosage form has a mass of about 50 to about 1000 mg, and the at least one first disintegration agent is present in the dosage form in an amount not exceeding 15%, with respect to the total weight of the dosage form. The second disintegration agent is present in the dosage form in an amount not exceeding 15% with respect to the total weight of the dosage form. The first and the second disintegration agent are present in total amounts that provide a weight ratio of about 1:1 to about 1:3, wherein the dosage form provides at least one of the in vitro or in vivo disintegration time that is less than 30 seconds, and has a friability of 1% or less according to the U.S. Pharmacopoeia test.

    摘要翻译： 本发明涉及快速崩解的可口服给药的固体剂型制剂，其包含至少一种活性成分，至少一种第一崩解剂，其是根据US Pharmacopoeia National Formulary US / NF至少一种C型甲基丙烯酸共聚物， 交联聚维酮的第二崩解剂或其交联聚维酮聚合物衍生物和不增加葡萄糖血液水平的非致龋剂稀释剂。 至少一种第一崩解剂不用作肠溶衣，旨在保护活性成分的绝缘涂层或旨在掩蔽味道或气味的涂层。 相对于剂型的总重量，固体剂型具有约50至约1000mg的质量，并且至少一种第一崩解剂以不超过15％的量存在于剂型中。 相对于剂型的总重量，第二崩解剂以不超过15％的量存在于剂型中。 第一和第二崩解剂以提供重量比为约1:1至约1:3的总量存在，其中该剂型提供至少一种体外或体内崩解时间小于30 秒，根据美国药典测试，其脆度为1％以下。